Tofacitinib Linked to Risk for Cardiac Events, Cancer, FDA Warns Tofacitinib Linked to Risk for Cardiac Events, Cancer, FDA Warns

The FDA has alerted the public to an increased risk of serious heart-related problems and cancer risk associated with the Janus kinase inhibitor tofacitinib (Xeljanz, Xeljanz XR).News Alerts
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Rheumatology News Alert Source Type: news